Clinical Focus

  • Nephrology

Academic Appointments

Professional Education

  • Doctor of Medicine, Univ of Texas Southwestern Medical Center (2015)
  • Bachelor of Science, University of Texas Austin (2010)
  • Fellowship: Stanford University Nephrology Fellowship (2021) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2018)
  • Residency: Baylor College of Medicine Internal Medicine Residency (2018) TX
  • Medical Education: University of Texas at Southwestern (2015) TX

Stanford Advisors

All Publications

  • SPRINT-A Kidney-Centric Narrative Review: Recent Advances in Hypertension. Hypertension (Dallas, Tex. : 1979) Hu, A. H., Chang, T. I. 2021: HYPERTENSIONAHA12116505


    Hypertension is a potent cardiovascular risk factor with deleterious end-organ effects and is especially prevalent among patients with chronic kidney disease. The SPRINT (Systolic Blood Pressure Intervention Trial) enrolled patients at an elevated cardiac risk including patients with mild to moderate chronic kidney disease and found that an intensive systolic blood pressure goal of <120 mm Hg significantly reduced the rates of adverse cardiovascular events and all-cause mortality and nonsignificantly reduced the rates of probable dementia; these results were consistent whether one had chronic kidney disease or not. However, results of intensive blood pressure therapy on chronic kidney disease progression were inconclusive, and there was an increased risk of incident chronic kidney disease and acute kidney injury, but the declines in kidney function appear to be hemodynamically driven and reversible. Overall, an intensive blood pressure target is effective in reducing cardiovascular disease and all-cause mortality and may reduce the risk of probable dementia in patients with mild to moderate chronic kidney disease. More studies are needed to determine its long-term effects on kidney function.

    View details for DOI 10.1161/HYPERTENSIONAHA.121.16505

    View details for PubMedID 34365808